Y-Biologics: utilizing innate assembly mechanisms in cell lines to create bispecific antibodies

Through its innovative, bispecific antibody platform ALiCE, Y-Biologics is discovering and developing next-generation immuno-oncology therapeutics.

Like Comment
Page of
Go to the profile of Y-Biologics


Founded in 2007, Y-Biologics is a renowned biotech company in South Korea for its expertise in antibody science. Since its foundation, we have dedicated ourselves to the discovery & development of novel antibody therapeutics. By utilizing our two platform technologies Y-max ABLTM & ALiCETM in R&D process, we aim to be a leading biopharmaceutical company in fields of immuno-oncology.

No comments yet.